Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.49 |
| ▸ | KDM5C | P41229 | 1/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5213150 | 0.87 | HPGD (0.57) | NPC1NAMPT | |
| SCHEMBL5213407 | 0.85 | TP53 (0.56) | KMT2AMEN1KDM4EKDM5AKDM5C | |
| SCHEMBL1568144 | 0.82 | RAB9A (0.64) | HIF1ANPC1PAX8KLF5TRPV1 | |
| SCHEMBL1767508 | 0.82 | TRPV1 (0.52) | HIF1ANPC1PAX8KLF5TRPV1 | |
| SCHEMBL5214225 | 0.81 | KMT2A (0.69) | HIF1ANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5215104 | 0.81 | KDM5B (0.71) | HIF1ANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL5212416 | 0.80 | KMT2A (0.52) | RAB9AKMT2AMEN1KDM4EKDM5A | |
| SCHEMBL5210637 | 0.79 | RAB9A (0.56) | NPC1RAB9AKMT2AMEN1NAMPT | |
| SCHEMBL16712995 | 0.78 | TRPV1 (0.62) | HIF1ANPC1PAX8KLF5TRPV1 | |
| SCHEMBL8945334 | 0.77 | POLB (0.54) | KMT2AMEN1KDM4EKDM5AKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | claimed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | claimed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7015237-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2006-03-21 | — | — | US | disclosed |
| EP-1530467-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| EP-1530475-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6881743-B2 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2004-10-21 | — | — | US | disclosed |
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | ROARK WILLIAM HOWARD (US) | 2004-01-29 | — | — | US | disclosed |
| WO-2004006931-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006912-A2 | COMBINATION OF AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 WITH CELECOXIB OR VALDECOXIB | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019053-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib | MMP13, MMP11, MMP10 | HIF1A 3489/4885NPC1 3123/4885PAX8 4655/4885 |
| US-20040209922-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | HIF1A 1315/4885NPC1 1342/4885PAX8 3590/4885 |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | HIF1A 1279/4885NPC1 1366/4885PAX8 3621/4885 |
| US-20040019054-A1 | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib | MMP13, MMP11, MMP10 | HIF1A 2939/4885NPC1 2608/4885PAX8 4648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.